Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 3

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 9A
Chunk 3
---
 over existence of inventory located at third parties and the net realizable value assessment of on-hand inventory and future purchases under firm commitments.

Management enhanced its precision and the level of evidence retained of reviews performed. In addition, management designed and implemented additional control activities over inventory located at third parties and the assessment of net realizable value of on-hand inventory and future purchases under firm commitments.

Changes in Internal Control over Financial Reporting

Other than with respect to the remediation efforts described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.